{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:53:45Z","timestamp":1790286825502,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09801-2","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:58:04Z","timestamp":1783058284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study"],"prefix":"10.1007","volume":"74","author":[{"given":"Meiling","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-2701","authenticated-orcid":false,"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"9801_CR1","doi-asserted-by":"publisher","first-page":"1210041","DOI":"10.3389\/fimmu.2023.1210041","volume":"14","author":"A Chinnici","year":"2023","unstructured":"Chinnici A, Beneforti L, Pegoraro F, Trambusti I, Tondo A, Favre C, Coniglio ML, Sieni E. Approaching hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1210041. https:\/\/doi.org\/10.3389\/fimmu.2023.1210041.","journal-title":"Front Immunol"},{"key":"9801_CR2","doi-asserted-by":"crossref","unstructured":"Allen CE, Mcclain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology. 2015(1):177\u2013182.","DOI":"10.1182\/asheducation-2015.1.177"},{"issue":"15","key":"9801_CR3","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, Mcclain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041\u201352.","journal-title":"Blood"},{"key":"9801_CR4","doi-asserted-by":"crossref","unstructured":"El-Mallawany NK, Curry CV, Allen CE. Haemophagocytic lymphohistiocytosis and epstein-barr virus: a complex relationship with diverse origins, expression and outcomes. British Journal of Haematology. 2021.","DOI":"10.1111\/bjh.17638"},{"key":"9801_CR5","first-page":"788349","volume":"06","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne AC, Aric\u00f3, Maurizio, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in hlh treatment: long term results of the cooperative hlh-2004 study. Blood. 2017;06:788349.","journal-title":"Blood"},{"issue":"17","key":"9801_CR6","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, Horne A, Aric\u00f2 M, Egeler RM, Henter JI. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the hlh-94 treatment protocol. Blood. 2011;118(17):4577\u201384.","journal-title":"Blood"},{"issue":"12","key":"9801_CR7","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/S2352-3026(19)30184-X","volume":"6","author":"N Sarah","year":"2019","unstructured":"Sarah N, Nancy, Berliner. Targeting the inflammatory cascade in haemophagocytic lymphohistiocytosis. Lancet Haematol. 2019;6(12):e602\u20133.","journal-title":"Lancet Haematol"},{"issue":"6","key":"9801_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","volume":"160","author":"XJ Xu","year":"2012","unstructured":"Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984\u2013e9901.","journal-title":"J Pediatr"},{"issue":"3","key":"9801_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (hlh): cd8\u2009+\u2009t cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735\u201343.","journal-title":"Blood"},{"issue":"6","key":"9801_CR10","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.jaci.2018.10.068","volume":"143","author":"S Humblet-Baron","year":"2019","unstructured":"Humblet-Baron S, Franckaert D, Dooley J, Ailal F, Bousfiha A, Deswarte C, Oleaga-Quintas C, Casanova JL, Bustamante J, Liston A. IFN-\u03b3 and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2019;143(6):2215\u2013e22267.","journal-title":"J Allergy Clin Immunol"},{"key":"9801_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trsl.2016.07.023","volume":"180","author":"V Buatois","year":"2017","unstructured":"Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, Johnson Z, Bracaglia C, De Benedetti F, de Min C, Kosco-Vilbois MH, Ferlin WG. Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis. Translational research: J Lab Clin Med. 2017;180:37\u2013e522.","journal-title":"Translational research: J Lab Clin Med"},{"issue":"19","key":"9801_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Diaz D, Henry JL, De Benedetti M, Grom F, Lapeyre A, Jacqmin G, Ballabio P, M., de Min C. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382(19):1811\u201322.","journal-title":"N Engl J Med"},{"issue":"9","key":"9801_CR13","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/bloodadvances.2023012217","volume":"8","author":"S Chandrakasan","year":"2024","unstructured":"Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson AP, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray AK, D\u00e1vila Salda\u00f1a B, Sarangi SN, Walkovich KJ, Yee JD, Zoref-Lorenz A, Allen CE. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024;8(9):2248\u201358.","journal-title":"Blood Adv"},{"key":"9801_CR14","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. Front Immunol. 2021;12:614704.","journal-title":"Front Immunol"},{"issue":"1","key":"9801_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","volume":"57","author":"H Wang","year":"2020","unstructured":"Wang H, Gu J, Liang X, Mao X, Wang Z, Huang W. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH. Semin Hematol. 2020;57(1):26\u201330.","journal-title":"Semin Hematol"},{"issue":"1","key":"9801_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41408-024-01056-0","volume":"14","author":"Y Song","year":"2024","unstructured":"Song Y, Zhou F, Du F, Wang Z, Bai L, Yao Y, Liu L, Ma X, Chen S, Wu D, He X. Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis. Blood cancer J. 2024;14(1):70.","journal-title":"Blood cancer J"},{"issue":"4","key":"9801_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12185-020-02936-4","volume":"112","author":"A Wei","year":"2020","unstructured":"Wei A, Ma H, Li Z, Zhang L, Zhang Q, Wang D, Lian H, Zhang R, Wang T. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112(4):568\u201376.","journal-title":"Int J Hematol"},{"issue":"5","key":"9801_CR18","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, Wang Z. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210\u20132.","journal-title":"Haematologica"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09801-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:58:10Z","timestamp":1783058290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9801"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09801-2","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study was approved by the appropriate institutional research ethics committee (Institutional Ethics Committee of the Children\u2019s Hospital of Chongqing Medical University). All procedures involving human participants were performed in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from their patients or their legal guardians prior to study enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We have obtained informed consent from the patients or their legal guardians for the use of their anonymized medical records, relevant medical images, and data for academic publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"69"}}